Trial Profile
A phase 1 trial of oral parathyroid hormone in healthy postmenopausal women.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2009
Price :
$35
*
At a glance
- Drugs Parathyroid hormone (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Unigene Laboratories
- 17 Mar 2009 Status changed from recruiting to completed, according to a Unigene media release.
- 17 Mar 2009 Results have been reported in a Unigene media release.
- 15 Oct 2008 New trial record.